CPA clinical trials

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study looks at new drug combinations for a type of lymphoma called Diffuse Large B-cell Lymphoma (DLBCL). It's for people whose DLBCL has come back or hasn't responded to previous treatments. Researchers are testing two different drug combinations to see how safe and effective they are.